TREM 1 antibody - Boehringer Ingelheim
Alternative Names: Triggering Receptor Expressed on Myeloid cells AntibodyLatest Information Update: 17 Aug 2023
At a glance
- Originator Boehringer Ingelheim
- Class Antibodies
- Mechanism of Action Triggering receptor expressed on myeloid cells-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Immunological disorders
Most Recent Events
- 11 Aug 2023 TREM 1 antibody - Boehringer Ingelheim is available for licensing as of 11 Aug 2023. https://www.boehringer-ingelheim.com/trem-1-antibody
- 09 Aug 2023 Phase-I clinical trials in Immunological disorders (unspecified route) prior August 2023 (Boehringer Ingelheim pipeline, August 2023)